SCHEMBL20072243

SCHEMBL20072243

CC(=O)Oc1cc(C)cc2cnccc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.41
ELANE P08246 1/20 0.38
MAPT P10636 2/20 0.37
IMPDH2 P12268 1/20 0.37
PKM P14618 1/20 0.37
NR3C1 P04150 1/20 0.37
KMT2A Q03164 1/20 0.36
PTPN1 P18031 1/20 0.36
CLK1 P49759 1/20 0.36
CLK2 P49760 1/20 0.36
CLK3 P49761 1/20 0.36
CDK5 Q00535 1/20 0.36
DYRK1A Q13627 1/20 0.36
CDK5R1 Q15078 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36
DYRK1B Q9Y463 1/20 0.36
ALDH1A1 P00352 2/20 0.36
HASPIN Q8TF76 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20072411 0.85 ALDH1A1 (0.41) HTTMAPTNR3C1KMT2AALDH1A1
SCHEMBL23841169 0.84 ELANE (0.38) ELANEMAPTIMPDH2NR3C1KMT2A
SCHEMBL9827336 0.79 KDM4E (0.47) HTTMAPTKMT2ACLK1CLK2
SCHEMBL23840987 0.78 ALDH1A1 (0.39) HTTMAPTNR3C1KMT2AALDH1A1
SCHEMBL5998660 0.78 KDM4E (0.50) HTTMAPTNR3C1KMT2AALDH1A1
SCHEMBL9035473 0.78 HTT (0.57) HTTELANEMAPTKMT2AALDH1A1
SCHEMBL9623200 0.76 IKBKB (0.47) MAPTIMPDH2PKMKMT2AALDH1A1
SCHEMBL9826930 0.75 MAOA (0.49) HTTMAPTKMT2ACLK1CLK2
SCHEMBL9826775 0.74 HTT (0.49) HTTMAPTPKMKMT2APTPN1
SCHEMBL9826866 0.74 HTT (0.49) HTTMAPTPKMKMT2APTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3526239-B1 HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES OLIPASS CORP (KR) 2021-11-03 EP disclosed
US-20190345202-A1 ANDROGEN RECEPTOR ANTISENSE OLIGONUCLEOTIDES OLIPASS CORPORATION (KR) 2019-11-14 US disclosed
US-20190337987-A1 EXON SKIPPING BY PEPTIDE NUCLEIC ACID DERIVATIVES OLIPASS CORPORATION (KR) 2019-11-07 US disclosed
WO-2018069764-A1 HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES OLIPASS CORPORATION (KR) 2018-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190345202-A1 ANDROGEN RECEPTOR ANTISENSE OLIGONUCLEOTIDES AR, NR5A1, NR5A2 HTT 3365/4885ELANE 3639/4885MAPT 3013/4885
US-20190337987-A1 EXON SKIPPING BY PEPTIDE NUCLEIC ACID DERIVATIVES PTBP1, RBM17, UPF1 HTT 1447/4885ELANE 874/4885MAPT 3836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.